Shares of Edgewise Therapeutics EWTX soared 30% in the pre-market trading on Thursday after it reported positive top-line data of EDG-7500 from an early-stage study in healthy subjects and Part A (single-dose arm) of a mid-stage study in patients with obstructive hypertrophic cardiomyopathy (HCM).
EWTX’s EDG-7500 Shows Superior Efficacy in Both Studies
Per the data readout from the phase I study in healthy adults, no meaningful changes in left ventricle ejection fraction (LVEF), an important predictor of mortality, were observed for all single and multiple ascending dose (SAD and MAD) subjects treated with a broad range of EDG-7500 doses. Dose-proportional increases in exposure were generally seen in both SAD and MAD cohorts.
The candidate was also overall well tolerated in the SAD and MAD cohorts of the phase I study and demonstrated a favorable safety profile, with no clinically meaningful changes or trends in vital signs, clinical chemistry, hematology or electrocardiograms.
In Part A of the phase II CIRRUS-HCM study, treatment with the 100 and 200 mg single doses of EDG-7500 resulted in a 67% mean reduction inresting left ventricular outflow tract (LVOT) pressure gradientand a 55% mean reduction in provokable (Valsalva) LVOT pressure gradient. Interestingly, gradient reduction was achieved without a meaningful change in LVEF.
Year to date, shares of Edgewise have rallied 74.3% compared with the industry’s 0.5% growth.
Image Source: Zacks Investment Research
In the 200 mg cohort, it was observed that treatment with the candidate also led to a 64% mean reduction in NT-proBNP, a key biomarker of heart failure. Per Edgewise, such robust outcomes underscore the potential of EDG-7500’s unique mechanism of action to treat diastolic dysfunction diseases, including non-obstructive HCM.
EWTX further reported that no patients in the phase I or the CIRRUS-HCM studies experienced an LVEF reduction below 50% across all administered doses of EDG-7500.
EWTX’s EDG-7500 Developmental Plans for Heart Diseases
Based on the encouraging clinical and preclinical data reported to date, Edgewise has started dosing the first patients with obstructive and non-obstructive HCM, in the 28-day Part B of the phase II CIRRUS-HCM study of EDG-7500, where there is a huge unmet medical need.
The study will also continue to evaluate the tolerability and PK of the candidate and its effects on LVOT pressure gradient, LVEF, biomarkers and measures of feel and function in the obstructive and non-obstructive HCM patient population.
Edgewise expects to report initial 28-day (Part B) data from the phase II CIRRUS-HCM study of EDG-7500 in the first quarter of 2025.
Apart from EDG-7500, EWTX is also currently evaluating its lead candidate, sevasemten, across several mid to late-stage studies to treat Becker and Duchenne muscular dystrophies. Sevasemten is an orally administered, first-in-class fast myosin inhibitor.
Edgewise Therapeutics, Inc. Price and Consensus
Edgewise Therapeutics, Inc. price-consensus-chart | Edgewise Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Edgewise currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. ILMN, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 EPS have moved up from $1.84 to $3.63. The consensus estimate for 2025 earnings has improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 5.9%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of KRYS have jumped 47.3%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.33 to 28 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 49%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Illumina, Inc. (ILMN) : Free Stock Analysis Report
Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report
Fulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report
Edgewise Therapeutics, Inc. (EWTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
